1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow MediMergent, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Evusheld (tixagevimab+cilgavimab) IM or IV - SARS-CoV-2 Infection | Phase 3 | Terminated | MediMergent, LLC | 550 | 2022-06-03 | 2023-09-08 |
COVID-19 (1) · Hematologic Neoplasms (1)
cilgavimab and tixagevimab drug combination (1)
United States (1)
Ralph Boccia, MD (1)